India, July 10 -- Merck Animal Health, a division of Merck & Co., Inc. (MRK), announced the U.S. Food and Drug Administration approval of BRAVECTO QUANTUM (fluralaner for extended-release injectable suspension) - a new, once-yearly injectable product to treat and protect dogs from fleas and ticks. The product is expected to be available at veterinary clinics and hospitals nationwide by August 2025.
BRAVECTO QUANTUM was first approved in Australia and New Zealand in 2023, followed by the European Union in 2024 and now the U.S. in 2025. In total, BRAVECTO QUANTUM is currently approved in more than 50 countries worldwide.
The company noted that BRAVECTO QUANTUM kills adult fleas and is indicated for the treatment and prevention of flea infes...